Replies to post #7687 on PharmaCyte Biotech Inc (PMCB)

[DITRstocks]

It is anticipated that the next obvious stage for Nuvilex, besides all of the preparatory work to get ready to run the trial, will be to initiate and complete a Phase 2b trial, which will most likely have similar, yet expanded endpoints and objectives from the Phase 2a trial, with several potential advances. It is likely in the future trial, Gemzar® will be used as a comparator against the Cell-in-a-Box® treatment, an increased schedule, and a larger number of patients.

$NVLX

[Cool_Trades]

We anticipate that in the next trial, Nuvilex’s results could be even more favorable since additional ifosfamide will be given over a greater number of cycles and there’s always a possibility to use them again if the tumor recurs. Moreover, the safety profile and quality of life demonstrated in its trial were outstanding and could prove to be one of the best of all the treatments under study. With all of these factors in mind, we believe that the value of Nuvilex’s pancreatic cancer treatment is ridiculously undervalued, as outlined in the valuation table below.

$NVLX